Retatrutide vs Exenatide
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: LY3437943, Triple G
Retatrutide is the heavy hitter of the new weight-loss drugs: a once-weekly injectable peptide that hits three receptors at once - GIP, GLP-1, and glucagon - earning it the nickname triple-G agonist. In a phase 2 trial it produced some of the largest weight loss ever recorded for a drug, up to roughly 24 percent of body weight at the top dose. It is investigational, made by Eli Lilly, and not yet FDA approved as of 2026.
Also: Byetta, Bydureon
Exenatide is the original GLP-1 receptor agonist and it came from an unlikely source: the saliva of the Gila monster, a venomous desert lizard. It is a synthetic 39-amino-acid peptide (a copy of the natural exendin-4) sharing about 50% of its sequence with human GLP-1, sold as the twice-daily Byetta (FDA-approved 2005) and the once-weekly Bydureon. It was the first drug to successfully turn the short-lived incretin hormone into a real diabetes therapy.
Key Comparison Insights
- Exenatide is FDA approved, while Retatrutide remains in research stages.
- Both peptides belong to the Weight Loss category, suggesting similar primary applications.
- Exenatide has stronger research evidence (FDA Approved) compared to Retatrutide (Human Trials).
Detailed Comparison
| Attribute | Retatrutide | Exenatide |
|---|---|---|
| Category | Weight Loss | Weight Loss |
| FDA Status | Not FDA Approved | FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Retatrutide combines three hormone signals into one molecule. The GLP-1 component curbs appetite and slows stomach emptying, the GIP component supports insulin response and may improve how fat tissue handles nutrients, and the added glucagon receptor activity is the novel piece: glucagon can increase energy expenditure and fat burning in the liver. The idea is that two arms cut how much you eat while the third raises how much you burn, which is why retatrutide is thought to push weight loss further than GLP-1-only drugs like semaglutide or even the dual GIP/GLP-1 agonist tirzepatide. The exact contribution of each receptor in humans is still being worked out, so consider the glucagon-driven energy-expenditure story a strong hypothesis rather than fully nailed down. | Exenatide binds and activates the GLP-1 receptor, triggering glucose-dependent insulin secretion, suppressing excess glucagon, slowing gastric emptying, and increasing satiety. The reason a lizard peptide beat human GLP-1 to market is durability: native GLP-1 is chewed up by the DPP-4 enzyme within about two minutes, while exendin-4 resists that enzyme and circulates with a half-life of roughly 2.4 hours. Endocrinologist John Eng isolated the peptide in the early 1990s after noting the Gila monster could go long stretches without eating while keeping blood sugar stable. The once-weekly Bydureon formulation traps the peptide in slowly dissolving polymer microspheres so a single injection releases drug over days. |
| Common Dosing | 4-12 mg weekly Once weekly, same day each week | 5-10 mcg twice daily or 2 mg weekly Twice daily (IR) or once weekly (ER) |
| Administration | Subcutaneous injection weekly | Subcutaneous injection |
| Typical Duration | Long-term use expected | Long-term / chronic use |
| Best Time to Take | Morning, same day each week | Before bed or morning (fasted) |
Possible Side Effects May vary by individual |
|
|
| Research Summary | The key human evidence is the phase 2 trial by Jastreboff and colleagues, published in the New England Journal of Medicine in 2023, which randomized 338 adults with obesity (without type 2 diabetes) over 48 weeks. Mean weight reduction reached about 24 percent at the 12 mg dose, and weight loss had not clearly plateaued by week 48, hinting the ceiling could be even higher. Among participants with prediabetes at baseline, a large majority returned to normal blood sugar. Side effects were dominated by gastrointestinal issues like nausea, vomiting, and diarrhea, the familiar pattern for this drug class, and were mostly dose-dependent. These are genuinely strong phase 2 results, but they are phase 2: larger and longer phase 3 trials are underway to confirm safety and durability, and retatrutide sold outside of trials is not an approved, quality-controlled medicine. | Exenatide is a long-approved drug with a deep human trial record, not an experimental compound. Its development is well documented in the peer-reviewed literature, including a 2012 review in Regulatory Peptides tracing it from Gila monster venom to an approved antidiabetic. In type 2 diabetes trials it lowered HbA1c and produced modest weight loss, with nausea being the most common side effect, usually fading over time. The EXSCEL cardiovascular outcomes trial found once-weekly exenatide was safe for the heart but did not show a statistically significant reduction in cardiovascular events, which is part of why newer agents like semaglutide and dulaglutide have largely overtaken it. There are rare post-marketing reports of acute pancreatitis, and it is not recommended in severe kidney impairment. Overall, strong human evidence, but now considered an older option in the class. |
Frequently Asked Questions: Retatrutide vs Exenatide
What is the difference between Retatrutide and Exenatide?
Retatrutide is a weight loss peptide that retatrutide is the heavy hitter of the new weight-loss drugs: a once-weekly injectable peptide that hits three receptors at once - gip, glp-1, and glucagon - earning it the nickname triple-g agonist. in a phase 2 trial it produced some of the largest weight loss ever recorded for a drug, up to roughly 24 percent of body weight at the top dose. it is investigational, made by eli lilly, and not yet fda approved as of 2026. Exenatide is a weight loss peptide that exenatide is the original glp-1 receptor agonist and it came from an unlikely source: the saliva of the gila monster, a venomous desert lizard. it is a synthetic 39-amino-acid peptide (a copy of the natural exendin-4) sharing about 50% of its sequence with human glp-1, sold as the twice-daily byetta (fda-approved 2005) and the once-weekly bydureon. it was the first drug to successfully turn the short-lived incretin hormone into a real diabetes therapy. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Retatrutide or Exenatide?
Neither is universally "better" - the choice depends on your specific goals. Retatrutide is typically used for weight loss purposes, while Exenatide is used for weight loss. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Retatrutide and Exenatide be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Retatrutide and Exenatide together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.